These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 20971003)

  • 1. N-substituted pyrrolidines and tetrahydrofurans as novel AMPAR positive modulators.
    Thewlis KM; Aldegheri L; Harries MH; Mookherjee C; Oliosi B; Ward SE
    Bioorg Med Chem Lett; 2010 Dec; 20(23):7116-9. PubMed ID: 20971003
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel pyrrolidine melanin-concentrating hormone receptor 1 antagonists with reduced hERG inhibition.
    Fox BM; Natero R; Richard K; Connors R; Roveto PM; Beckmann H; Haller K; Golde J; Xiao SH; Kayser F
    Bioorg Med Chem Lett; 2011 Apr; 21(8):2460-7. PubMed ID: 21414780
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improving the developability profile of pyrrolidine progesterone receptor partial agonists.
    Kallander LS; Washburn DG; Hoang TH; Frazee JS; Stoy P; Johnson L; Lu Q; Hammond M; Barton LS; Patterson JR; Azzarano LM; Nagilla R; Madauss KP; Williams SP; Stewart EL; Duraiswami C; Grygielko ET; Xu X; Laping NJ; Bray JD; Thompson SK
    Bioorg Med Chem Lett; 2010 Jan; 20(1):371-4. PubMed ID: 19926282
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and biological evaluation of pyrrolidine derivatives as novel and potent sodium channel blockers for the treatment of ischemic stroke.
    Seki M; Tsuruta O; Tatsumi R; Soejima A
    Bioorg Med Chem Lett; 2013 Jul; 23(14):4230-4. PubMed ID: 23743284
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).
    Boss C; Roch C
    Expert Opin Ther Pat; 2016; 26(3):409-15. PubMed ID: 26593218
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mallotoxin is a novel human ether-a-go-go-related gene (hERG) potassium channel activator.
    Zeng H; Lozinskaya IM; Lin Z; Willette RN; Brooks DP; Xu X
    J Pharmacol Exp Ther; 2006 Nov; 319(2):957-62. PubMed ID: 16928897
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of biaryl sulfone derivatives as antagonists of the histamine H₃ receptor: discovery of (R)-1-(2-(4'-(3-methoxypropylsulfonyl)biphenyl-4-yl)ethyl)-2-methylpyrrolidine (APD916).
    Semple G; Santora VJ; Smith JM; Covel JA; Hayashi R; Gallardo C; Ibarra JB; Schultz JA; Park DM; Estrada SA; Hofilena BJ; Smith BM; Ren A; Suarez M; Frazer J; Edwards JE; Hart R; Hauser EK; Lorea J; Grottick AJ
    Bioorg Med Chem Lett; 2012 Jan; 22(1):71-5. PubMed ID: 22172695
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aminomethyl tetrahydronaphthalene biphenyl carboxamide MCH-R1 antagonists--Increasing selectivity over hERG.
    Meyers KM; Kim N; Méndez-Andino JL; Hu XE; Mumin RN; Klopfenstein SR; Wos JA; Mitchell MC; Paris JL; Ackley DC; Holbert JK; Mittelstadt SW; Reizes O
    Bioorg Med Chem Lett; 2007 Feb; 17(3):814-8. PubMed ID: 17107791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The action of a novel fluoroquinolone antibiotic agent antofloxacin hydrochloride on human-ether-à-go-go-related gene potassium channel.
    Guo J; Han SN; Liu JX; Zhang XM; Hu ZS; Shi J; Zhang LR; Zhao ZZ; Zhang Z
    Basic Clin Pharmacol Toxicol; 2010 Aug; 107(2):643-9. PubMed ID: 20662825
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Microwave assisted synthesis of spirocyclic pyrrolidines -σ1 receptor ligands with modified benzene-N-distance.
    Jasper A; Schepmann D; Lehmkuhl K; Vela JM; Buschmann H; Holenz J; Wünsch B
    Eur J Med Chem; 2012 Jul; 53():327-36. PubMed ID: 22578786
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fluorescently labeled analogues of dofetilide as high-affinity fluorescence polarization ligands for the human ether-a-go-go-related gene (hERG) channel.
    Singleton DH; Boyd H; Steidl-Nichols JV; Deacon M; Groot MJ; Price D; Nettleton DO; Wallace NK; Troutman MD; Williams C; Boyd JG
    J Med Chem; 2007 Jun; 50(13):2931-41. PubMed ID: 17536794
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The discovery and structure-activity relationships of 2-(piperidin-3-yl)-1H-benzimidazoles as selective, CNS penetrating H1-antihistamines for insomnia.
    Lavrador-Erb K; Ravula SB; Yu J; Zamani-Kord S; Moree WJ; Petroski RE; Wen J; Malany S; Hoare SR; Madan A; Crowe PD; Beaton G
    Bioorg Med Chem Lett; 2010 May; 20(9):2916-9. PubMed ID: 20347297
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of benzoylisoindolines as a novel class of potent, selective and orally active GlyT1 inhibitors.
    Pinard E; Alberati D; Bender M; Borroni E; Brom V; Burner S; Fischer H; Hainzl D; Halm R; Hauser N; Jolidon S; Lengyel J; Marty HP; Meyer T; Moreau JL; Mory R; Narquizian R; Norcross RD; Schmid P; Wermuth R; Zimmerli D
    Bioorg Med Chem Lett; 2010 Dec; 20(23):6960-5. PubMed ID: 20974532
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Substituted benzoxazinones as potent positive allosteric AMPA receptor modulators: part II.
    Mueller R; Rachwal S; Tedder ME; Li YX; Zhong S; Hampson A; Ulas J; Varney M; Nielsson L; Rogers G
    Bioorg Med Chem Lett; 2011 Jul; 21(13):3927-30. PubMed ID: 21636273
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 1,4-Dihydroindeno[1,2-c]pyrazoles with acetylenic side chains as novel and potent multitargeted receptor tyrosine kinase inhibitors with low affinity for the hERG ion channel.
    Dinges J; Albert DH; Arnold LD; Ashworth KL; Akritopoulou-Zanze I; Bousquet PF; Bouska JJ; Cunha GA; Davidsen SK; Diaz GJ; Djuric SW; Gasiecki AF; Gintant GA; Gracias VJ; Harris CM; Houseman KA; Hutchins CW; Johnson EF; Li H; Marcotte PA; Martin RL; Michaelides MR; Nyein M; Sowin TJ; Su Z; Tapang PH; Xia Z; Zhang HQ
    J Med Chem; 2007 May; 50(9):2011-29. PubMed ID: 17425296
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aminomethyl tetrahydronaphthalene ketopiperazine MCH-R1 antagonists--Increasing selectivity over hERG.
    Meyers KM; Méndez-Andino JL; Colson AO; Warshakoon NC; Wos JA; Mitchell MC; Hodge KM; Howard JM; Ackley DC; Holbert JK; Mittelstadt SW; Dowty ME; Obringer CM; Reizes O; Hu XE
    Bioorg Med Chem Lett; 2007 Feb; 17(3):819-22. PubMed ID: 17107796
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Flunarizine is a highly potent inhibitor of cardiac hERG potassium current.
    Trepakova ES; Dech SJ; Salata JJ
    J Cardiovasc Pharmacol; 2006 Feb; 47(2):211-20. PubMed ID: 16495758
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel potent human ether-a-go-go-related gene (hERG) potassium channel enhancers and their in vitro antiarrhythmic activity.
    Zhou J; Augelli-Szafran CE; Bradley JA; Chen X; Koci BJ; Volberg WA; Sun Z; Cordes JS
    Mol Pharmacol; 2005 Sep; 68(3):876-84. PubMed ID: 15976038
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SAR profiles of spirocyclic nicotinamide derived selective HDAC1/HDAC2 inhibitors (SHI-1:2).
    Methot JL; Hamblett CL; Mampreian DM; Jung J; Harsch A; Szewczak AA; Dahlberg WK; Middleton RE; Hughes B; Fleming JC; Wang H; Kral AM; Ozerova N; Cruz JC; Haines B; Chenard M; Kenific CM; Secrist JP; Miller TA
    Bioorg Med Chem Lett; 2008 Dec; 18(23):6104-9. PubMed ID: 18951790
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exploring chemical substructures essential for HERG k(+) channel blockade by synthesis and biological evaluation of dofetilide analogues.
    ; Guo D; Klaasse E; de Vries H; Brussee J; Nalos L; Rook MB; Vos MA; van der Heyden MA; Ijzerman AP
    ChemMedChem; 2009 Oct; 4(10):1722-32. PubMed ID: 19725081
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.